Posted:
Cochlear announced that they recently completed patient enrollment across two pivotal studies of an investigational fully implantable hearing system. The milestone was reported November 3. The two studies, called ELEVATE and ENTERPRISE, enrolled 92 adults in total, 56 across 11 sites in the United States and 36 across five sites in Australia and France.
A fully implantable hearing system places all components, including the microphone, beneath the skin, removing the externally worn sound processor that conventional cochlear implants require. The company says a primary analysis of safety and effectiveness is planned at six months after surgery, with follow-up continuing to 12 months. Cochlear’s chief technology officer said the company does not see fully implantable technology replacing conventional cochlear implants, but expects both to have a place, with the fully implantable option suiting some patients.
This is an investigational device still in clinical testing, not an approved or available product. Completing enrollment is a step in the trial process; results, regulatory review, and any path to availability would follow. The development parallels MED-EL’s recent European launch of a fully implantable cochlear implant, signaling growing industry interest in the approach.
Learn more here.


